Channelling bias and the incidence of gastrointestinal haemorrhage in users of meloxicam, coxibs, and older, non-specific non-steroidal anti-inflammatory drugs

No abstract is available for this paper.

• Publication year

  2003

• Venue

  Gut

• Publication date

  2003-08-11

• Fields of study

  Medicine

• Identifiers
  DOI 10.1136/gut.52.9.1265PMID 12912856PMCID PMC1773795
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Observational study of upper gastrointestinal haemorrhage in elderly patients given selective cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs

  2002cited by this paper
• Presents from patient

  2002cited by this paper
• Upper gastrointestinal tolerability of celecoxib compared with diclofenac in the treatment of osteoarthritis and rheumatoid arthritis.

  2002cited by this paper
• Efficacy, tolerability, and upper gastrointestinal safety of celecoxib for treatment of osteoarthritis and rheumatoid arthritis: systematic review of randomised controlled trials

  2002cited by this paper
• Safety and efficacy of meloxicam in the treatment of osteoarthritis: a 12-week, double-blind, multiple-dose, placebo-controlled trial. The Meloxicam Osteoarthritis Investigators.

  2000cited by this paper
• Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group.

  2000cited by this paper
• Reduced risk of upper gastrointestinal ulcer complications with celecoxib, a novel COX-2 inhibitor

  2000cited by this paper
• Gastrointestinal tolerability of the selective cyclooxygenase-2 (COX-2) inhibitor rofecoxib compared with nonselective COX-1 and COX-2 inhibitors in osteoarthritis.

  2000cited by this paper
• Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study.

  2000cited by this paper
• Baseline risk of gastrointestinal disorders among new users of meloxicam, ibuprofen, diclofenac, naproxen and indomethacin

  2000cited by this paper
• The incidence of adverse events and risk factors for upper gastrointestinal disorders associated with meloxicam use amongst 19,087 patients in general practice in England: cohort study.

  2000cited by this paper
• Upper gastrointestinal tolerability of celecoxib, a COX-2 specific inhibitor, compared to naproxen and placebo.

  2000cited by this paper
• Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs.

  1999cited by this paper
• Metabolism and elimination of 14C-donepezil in healthy volunteers: a single-dose study.

  1998cited by this paper
• Use of the UK General Practice Research Database for pharmacoepidemiology.

  1998cited by this paper
• Association of upper gastrointestinal toxicity of non-steroidal anti-inflammatory drugs with continued exposure: cohort study

  1997cited by this paper
• Primary non-compliance with prescribed medication in primary care.

  1993cited by this paper
• Validation of information recorded on general practitioner based computerised data resource in the United Kingdom.

  1991cited by this paper
• A general parametric approach to the meta-analysis of randomized clinical trials.

  1991cited by this paper
• The central role of the propensity score in observational studies for causal effects

  1983cited by this paper

• Assessment of a Modified High‐Dimensional Propensity Score Approach for UK Electronic Health Record Data: Evaluating Upper Gastrointestinal Safety of NSAIDs and COX‐2 Inhibitors

  2026cites this paper
• Synergistic enhancement of anti-migraine efficacy through supramolecular self-assembly of tizanidine with meloxicam.

  2025cites this paper
• Evaluation of Coastal Sediments for Heavy Metal Contamination, Bhavnagar Coast, Gulf of Khambhat, Gujarat, India

  2024cites this paper
• Channeling of New Neuropsychiatric Drugs—Impact on Safety and Effectiveness Studies

  2023cites this paper
• Pharmacology, safety, efficacy and clinical uses of the COX‐2 inhibitor robenacoxib

  2022cites this paper
• Using epidemiological methods to quantify the risk of serious infections in children with atopic dermatitis

  2021cites this paper
• Electronic Health Record Databases

  2019cites this paper
• Differences in cardiovascular safety with non‐steroidal anti‐inflammatory drug therapy—A nationwide study in patients with osteoarthritis

  2019cites this paper
• Ibuprofen and Paracetamol: Acceptably Safe for All?

  2018cites this paper
• Randomized clinical trials and observational studies in the assessment of drug safety.

  2018cites this paper
• Assessment of channeling bias among initiators of glucose-lowering drugs: A UK cohort study

  2017cites this paper
• Unintended effects of anti-hyperglycaemic drugs studied in population-based cohorst

  2017cites this paper
• Performance of the High‐dimensional Propensity Score in a Nordic Healthcare Model

  2017cites this paper
• Unintended effects of anti-hyperglycaemic drugs studied in population-based cohorts

  2017cites this paper
• [Nonsteroidal Anti-inflammatory Drug and Aspirin-induced Peptic Ulcer Disease].

  2016cites this paper
• Non steroidal anti-inflammatory drugs and cardiovascular risk: identifying evidence for channelling bias in a population based study

  2015cites this paper
• Information for rational drug prescribing to older patients : Availability and applicability

  2014cites this paper
• Heavy metal content in the beach sediment with respect to contamination levels and sediment quality guidelines: a study at Kalpakkam coast, southeast coast of India

  2014cites this paper
• Monoclonal gammopathy of undetermined significance and anti-TNF-α treatment: comments on the article by Smale and Lawson

  2013cites this paper
• High-dimensional versus conventional propensity scores in a comparative effectiveness study of coxibs and reduced upper gastrointestinal complications

  2013cites this paper
• Abdominal discomfort in patients with rheumatoid arthritis is associated with physical and mental function, self-reported disease activity, and use of anti-inflammatory medication

  2013cites this paper
• Examples of Automated Databases

  2013cites this paper
• Nonbenzodiazepine hypnotics are associated with an increased risk of hip fracture in residential aged care facilities

  2013cites this paper
• The European Network of Centres for Pharmacoepidemiology and Pharmacovigilance (ENCePP)

  2012cites this paper
• Targeting Outpatient Drug Safety

  2012cites this paper
• Automatisierte Verfahren in der Arzneimittelsicherheitsforschung

  2012cites this paper
• Assessment of nutritional status and analytical methods.

  2012cites this paper
• Individual NSAIDs and upper gastrointestinal complications: a systematic review and meta-analysis of observational studies (the SOS project).

  2012influential citation
• Individual NSAIDs and Upper Gastrointestinal Complications

  2012cites this paper
• Frequency of nonsteroidal anti-inflammatory drug-associated ulcers

  2012cites this paper
• Оптимізація аналгетичної і протизапальної терапії в амбулаторній травматологічній практиці

  2012cites this paper
• Cardiovascular Risk with Non-Steroidal Anti-Inflammatory Drugs: Systematic Review of Population-Based Controlled Observational Studies

  2011cites this paper
• In vitro effect of carprofen and meloxicam on the conductance and permeability to mannitol and the histologic appearance of the gastric mucosa of dogs.

  2011cites this paper
• Ameliorative Effect of Ocimum Sanctum on Meloxicam Induced Toxicity in Wistar Rats

  2011cites this paper
• Long-term opioid management for chronic noncancer pain.

  2010cites this paper
• Hospitalizations for gastrointestinal and cardiovascular events in the CADEUS cohort of traditional or Coxib NSAID users.

  2010cites this paper
• Meloxicam and meloxicam-beta-cyclodextrin complex in model membranes: effects on the properties and enzymatic lipolysis of phospholipid monolayers in relation to anti-inflammatory activity.

  2009cites this paper
• The case-crossover study design in pharmacoepidemiology

  2009cites this paper
• Evidence for endoscopic ulcers as meaningful surrogate endpoint for clinically significant upper gastrointestinal harm.

  2009cites this paper
• COX‐2 inhibitors: complex association with lower risk of hospitalization for gastrointestinal events compared to traditional NSAIDs plus proton pump inhibitors

  2009influential citation
• Risk of Upper Gastrointestinal Complications Associated with Cyclooxygenase‐2 Selective and Nonselective Nonsteroidal Antiinflammatory Drugs

  2009cites this paper
• Iatrogenic Effects of COX-2 Inhibitors in the US Population

  2009cites this paper
• The pattern of use of non‐steroidal anti‐inflammatory drugs (NSAIDs) from 1997 to 2005: a nationwide study on 4.6 million people

  2008cites this paper
• A signal of increased risk of hypoglycaemia with angiotensin receptor blockers caused by confounding.

  2008cites this paper
• Synergistic interaction between meloxicam and aminoguanidine in formalin‐induced nociception in mice

  2008cites this paper
• Technology assessment report commissioned by the HTA Programme on behalf of The National Institute for Clinical Excellence

  2008cites this paper
• Cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs (etodolac, meloxicam, celecoxib, rofecoxib, etoricoxib, valdecoxib and lumiracoxib) for osteoarthritis and rheumatoid arthritis: a systematic review and economic evaluation.

  2008cites this paper
• Does the varied use of NSAIDs explain the differences in the risk of myocardial infarction?

  2008cites this paper
• Changes in the characteristics of patients prescribed selective cyclooxygenase 2 inhibitors after the 2004 withdrawal of rofecoxib.

  2008cites this paper
• Chitosan-alginate blend films for the transdermal delivery of meloxicam

  2008cites this paper
• What is the harm-benefit ratio of Cox-2 inhibitors?

  2008cites this paper
• Development of NSAIDs prescription indicators based on health outcomes

  2008cites this paper
• National mortality following upper gastrointestinal or cardiovascular events in older veterans with recent nonsteroidal anti‐inflammatory drug use

  2008cites this paper
• Long-term opioid therapy for chronic noncancer pain: a systematic review and meta-analysis of efficacy and safety.

  2008cites this paper
• Evaluation of Risk Profiles for Gastrointestinal and Cardiovascular Adverse Effects in Nonselective NSAID and COX-2 Inhibitor Users

  2008cites this paper
• Risk of serious upper gastrointestinal events with concurrent use of NSAIDs and SSRIs: a case-control study in the general population

  2007cites this paper
• Risk of upper gastrointestinal complications among users of traditional NSAIDs and COXIBs in the general population.

  2007cites this paper
• Risk of upper gastrointestinal events with the use of various NSAIDs: A case-control study in a general population

  2007cites this paper
• Incidence of spontaneous notifications of adverse reactions with aceclofenac, meloxicam, and rofecoxib during the first year after marketing in the United Kingdom

  2007cites this paper
• Cyclo-oxygenase-2 selective inhibitors and nonsteroidal anti-inflammatory drugs: balancing gastrointestinal and cardiovascular risk

  2007cites this paper
• Choosing nonselective NSAIDs and selective COX-2 inhibitors in the elderly. A clinical use pathway.

  2007cites this paper
• Is There a Tension between Clinical Practice and Reimbursement Policy? The Case of Osteoarthritis Prescribing Practices in Ontario.

  2007cites this paper
• Developments in Post‐marketing Comparative Effectiveness Research

  2007cites this paper
• Development of NSAIDs prescription indicators based on health outcomes

  2007cites this paper
• Selective COX-2 inhibitors: a promise unfulfilled?

  2007cites this paper
• Quantitative assessment of the gastrointestinal and cardiovascular risk‐benefit of celecoxib compared to individual NSAIDs at the population level

  2007cites this paper
• Drug–drug interactions between antithrombotic medications and the risk of gastrointestinal bleeding

  2007cites this paper
• Selective COX-2 Inhibitors: A Promise Unfulfilled?

  2007cites this paper
• Increase in Nonfatal Digestive Perforations and Haemorrhages following Introduction of Selective NSAIDs: a Public Health Concern

  2007cites this paper
• Evaluating Short-Term Drug Effects Using a Physician-Specific Prescribing Preference as an Instrumental Variable

  2006cites this paper
• Investigations on analgesic, anti-inflammatory and ulcerogenic potential of meloxicam solid dispersion prepared with skimmed milk.

  2006cites this paper
• The epidemiology of prostate cancer--with a focus on nonsteroidal anti-inflammatory drugs.

  2006cites this paper
• Risk of serious NSAID‐related gastrointestinal events during long‐term exposure: a systematic review

  2006cites this paper
• Increase in nonfatal digestive perforations and haemorrhages following introduction of selective NSAIDs: a public health concern.

  2006cites this paper
• Use of cyclo‐oxygenase 2 inhibitors (COX‐2) and prescription non‐steroidal anti‐inflammatory drugs (NSAIDS) in UK and USA populations. Implications for COX‐2 cardiovascular profile

  2006cites this paper
• Sensitivity analysis and external adjustment for unmeasured confounders in epidemiologic database studies of therapeutics

  2006cites this paper
• [Patterns of non steroidal anti-inflammatory drug use in ambulatory care].

  2006cites this paper
• A review of the application of propensity score methods yielded increasing use, advantages in specific settings, but not substantially different estimates compared with conventional multivariable methods.

  2006cites this paper
• A European's Perspective of COX-2 Drug Safety

  2006cites this paper
• Relative Value of the NSAIDs, Including COX-2 Inhibitors and Meloxicam

  2006cites this paper
• Analgesic, Anti-Inflammatory and Ulcerogenic Studies of Meloxicam Solid Dispersion in Rodents

  2006cites this paper
• Profil des utilisateurs d’anti-inflammatoires non stéroïdiens

  2006cites this paper
• Nonsteroidal anti-inflammatory drugs (NSAIDs), cyxlooxygenase-2 selective inhibitors (coxibs) and gastrointestinal harm: review of clinical trials and clinical practice

  2006cites this paper
• Correction: Tolerability and adverse events in clinical trials of celecoxib in osteoarthritis and rheumatoid arthritis: systematic review and meta-analysis of information from company clinical trial reports

  2005cites this paper
• Prevalence of risk factors for suicide in patients prescribed venlafaxine, fluoxetine, and citalopram

  2005cites this paper
• The trade‐off between cardiovascular and gastrointestinal effects of rofecoxib

  2005cites this paper
• Dextropropoxyphene

  2005cites this paper
• Comparison of preemptive analgesic effects of a single dose of nonopioid analgesics for pain management after ambulatory surgery: A prospective, randomized, single-blind studyin Turkish patients.

  2005cites this paper
• Taking stock of coxibs

  2005cites this paper
• Gastrointestinal adverse effects of non-steroidal anti-inflammatory drugs

  2005cites this paper
• Haemorrhagic gastritis and bleeding following rofecoxib administration.

  2005cites this paper
• The trade‐off between cardiovascular and gastrointestinal effects of rofecoxib

  2005cites this paper
• The coxib NSAIDs: potential clinical and pharmacologic importance in veterinary medicine.

  2005cites this paper
• Risk of adverse gastrointestinal outcomes in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis

  2005cites this paper
• Risk of myocardial infarction in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis

  2005cites this paper
• Meloxicam: a reappraisal of pharmacokinetics, efficacy and safety

  2005cites this paper
• Tolerability and adverse events in clinical trials of celecoxib in osteoarthritis and rheumatoid arthritis: systematic review and meta-analysis of information from company clinical trial reports

  2005cites this paper
• Potential interactions between non‐steroidal anti‐inflammatory drugs and other drugs

  2005cites this paper
• Global functions at the World Health Organization

  2005cites this paper
• Are rates of gastrointestinal bleeding higher following the introduction of COX-2 inhibitors?

  2005cites this paper